Keyphrases
Clinical Features
100%
Progressive multifocal Leukoencephalopathy
100%
JC Virus
100%
Rheumatic Diseases
20%
Diverse Populations
20%
Hematological Malignancies
20%
Monoclonal Antibody
20%
Brain Diseases
20%
Neurological Disorders
20%
Multiple Sclerosis Treatment
20%
Psoriasis
20%
Gray Matter
20%
Virus
20%
Population at Risk
20%
HIV Epidemic
20%
Rituximab
20%
Crohn's Disease
20%
Encephalopathy
20%
Combined Antiretroviral Therapy (cART)
20%
Immune Reconstitution
20%
Efalizumab
20%
Meningitis
20%
Natalizumab
20%
JC Polyomavirus (JCPyV)
20%
JC Virus Granule Cell Neuronopathy
20%
Neuroscience
Progressive Multifocal Leukoencephalopathy
100%
JC Virus
100%
Brain Disease
33%
Monoclonal Antibody
16%
Gray Matter
16%
Treatment of Multiple Sclerosis
16%
Nervous System Disorder
16%
Granule Cell
16%
Rituximab
16%
Natalizumab
16%
Efalizumab
16%
Human Immunodeficiency Virus
16%
Meningitis
16%
Immunology and Microbiology
JC Virus
100%
Treatment of Multiple Sclerosis
16%
Immune Reconstitution Inflammatory Syndrome
16%
Virus
16%
Human Immunodeficiency Virus
16%
Monoclonal Antibody
16%
Rituximab
16%
Natalizumab
16%
Rheumatic Disease
16%
Gray Matter
16%
Efalizumab
16%
Granule Cell
16%
Meningitis
16%
Crohn's Disease
16%